Jazz Pharmaceuticals plc (JAZZ) is expecting 2.28% growth in the next quarter: What can investors do to maximize their returns?

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) kicked off on Monday, down -3.34% from the previous trading day, before settling in for the closing price of $121.65. Over the past 52 weeks, JAZZ has traded in a range of $99.06-$134.17.

Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 15.52%. While this was happening, its average annual earnings per share was recorded 10.58%. With a float of $58.21 million, this company’s outstanding shares have now reached $62.26 million.

Considering the fact that the conglomerate employs 2800 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 77.79%, operating margin of 18.49%, and the pretax margin is 9.98%.

Jazz Pharmaceuticals plc (JAZZ) Insider Activity

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Jazz Pharmaceuticals plc is 3.72%, while institutional ownership is 97.16%. The most recent insider transaction that took place on Nov 08 ’24, was worth 456,617. In this transaction EVP & Chief Legal Officer of this company sold 3,700 shares at a rate of $123.41, taking the stock ownership to the 33,048 shares. Before that another transaction happened on Nov 08 ’24, when Company’s Officer proposed sale 3,700 for $123.41, making the entire transaction worth $456,632.

Jazz Pharmaceuticals plc (JAZZ) Earnings and Forecasts

According to the Wall Street analysts, stocks earnings will be around 10.58% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.48% during the next five years compared to -3.53% drop over the previous five years of trading.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Trading Performance Indicators

Take a look at Jazz Pharmaceuticals plc’s (JAZZ) current performance indicators. Last quarter, stock had a quick ratio of 3.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.74. Likewise, its price to free cash flow for the trailing twelve months is 6.16.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 6.94, a number that is poised to hit 5.92 in the next quarter and is forecasted to reach 21.60 in one year’s time.

Technical Analysis of Jazz Pharmaceuticals plc (JAZZ)

Compared to the last year’s volume of 0.68 million, its volume of 0.83 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 59.45%. Additionally, its Average True Range was 3.45.

During the past 100 days, Jazz Pharmaceuticals plc’s (JAZZ) raw stochastic average was set at 61.91%, which indicates a significant increase from 43.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.33% in the past 14 days, which was higher than the 29.26% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $112.44, while its 200-day Moving Average is $112.92. Nevertheless, the first resistance level for the watch stands at $121.16 in the near term. At $124.73, the stock is likely to face the second major resistance level. The third major resistance level sits at $126.58. If the price goes on to break the first support level at $115.74, it is likely to go to the next support level at $113.89. Should the price break the second support level, the third support level stands at $110.32.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Key Stats

The company with the Market Capitalisation of 6.96 billion has total of 60,455K Shares Outstanding. Its annual sales at the moment are 3,834 M in contrast with the sum of 414,830 K annual income. Company’s last quarter sales were recorded 1,055 M and last quarter income was 215,060 K.